Antibodies targeting ADAM17 reverse neurite outgrowth inhibition by myelin-associated inhibitors
Life Science Alliance · 2025-06 · 8 (6) · e202403126
DOI: 10.26508/lsa.202403126 ↗Kurz gefasst
Fachartikel in der Zeitschrift Life Science Alliance, online erschienen am 25.03.2025. Verfasst von Nayanendu Saha und 5 weiteren Autor:innen. Beteiligte Einrichtung: Structural Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA sahan@mskcc.org. Hauptthemen laut MEDLINE: ADAM17 Protein, Neuronal Outgrowth, Antibodies, Monoclonal. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIA NIH HHS, New York State Spinal Cord Injury Research Program.
Abstract (Originalsprache)
Upon spinal cord injury, axons attempting to regenerate need to overcome the repulsive actions of myelin-associated inhibitors, including the myelin-associated glycoprotein, Nogo-A, and the oligodendrocyte myelin glycoprotein. These inhibitors bind and signal through a neuronal receptor/co-receptor/transducer complex composed of NgR1, Lingo-1, and p75. Consequently, p75 is cleaved by alpha secretase followed by gamma-secretase, triggering downstream signaling that inhibits axonal regrowth. ADAM10 and ADAM17 are both known to function as alpha secretases in neurons. Here we show that ADAM17, and not ADAM10, is the alpha secretase that recognizes and cleaves p75, when it is a part of a 5-component neuron-myelin signaling complex comprising NgR1, Lingo-1, p75, GT1b, and a myelin inhibitor. Importantly, we demonstrate the ability of inhibitory anti-ADAM17 mAbs to abrogate the cleavage of p75 in a neuroblastoma-glioma cell line and reverse the neurite outgrowth inhibition by myelin-associated inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Structural Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA sahan@mskcc.org.
- Molecular Cytology Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY, USA.
- Structural Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA nikolovd@mskcc.org.
ORCID-Profile: Nayanendu Saha, Murray J Tipping, Dimitar B Nikolov
Förderung
- NCI NIH HHS
- NIA NIH HHS
- New York State Spinal Cord Injury Research Program
- National Institutes of Health
- NIH/NCI Cancer Center Support Grant to MSKCC
Zitieren
APA
Saha, N., Chan, E., Mendoza, R. P., Romin, Y., Tipping, M. J., & Nikolov, D. B. (2025). Antibodies targeting ADAM17 reverse neurite outgrowth inhibition by myelin-associated inhibitors. Life Science Alliance, 8(6), e202403126. https://doi.org/10.26508/lsa.202403126
Vancouver
Saha N, Chan E, Mendoza RP, Romin Y, Tipping MJ, Nikolov DB. Antibodies targeting ADAM17 reverse neurite outgrowth inhibition by myelin-associated inhibitors. Life Science Alliance. 2025;8(6):e202403126. doi:10.26508/lsa.202403126
BibTeX
@article{Saha2025,
author = {Saha, Nayanendu and Chan, Eric and Mendoza, Rachelle P and Romin, Yevgeniy and Tipping, Murray J and Nikolov, Dimitar B},
title = {Antibodies targeting ADAM17 reverse neurite outgrowth inhibition by myelin-associated inhibitors},
journal = {Life Science Alliance},
year = {2025},
volume = {8},
number = {6},
pages = {e202403126},
doi = {10.26508/lsa.202403126}
}
EUVIMED